Zelminemab
Modify Date: 2024-01-10 20:09:36
Zelminemab structure
|
Common Name | Zelminemab | ||
|---|---|---|---|---|
| CAS Number | 2225850-33-7 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of ZelminemabZelminemab (AMG-301) is a human monoclonal antibody that inhibits PACAP type I (PAC1) receptor[1]. |
| Name | Zelminemab |
|---|
| Description | Zelminemab (AMG-301) is a human monoclonal antibody that inhibits PACAP type I (PAC1) receptor[1]. |
|---|---|
| Related Catalog | |
| In Vivo | Zelminemab（10 mg/kg；i.v.；一次）降低 TCC 中的伤害性神经元活动[2]。 Animal Model: Sprague-Dawley rats, electricalstimulation was performed on the intact dura mater abovethe middle meningeal artery[2]. Dosage: 10 mg/kg Administration: i.v.; once Result: Induced an inhibition of stimulus-evoked nociceptive activity in the trigeminocervical com-plex (TCC). |
| References |
| No Any Chemical & Physical Properties |